Association between Polymorphism in the Janus Kinase 2 (JAK2) Gene and Selected Performance Traits in Cattle and Sheep. [PDF]
Animals (Basel), 2023 Oster N +5 more
europepmc +3 more sources
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 [PDF]
Leukemia, 2020 La Rosee F, Bremer HC, Gehrke I, Kehr A, Hochhaus A, Birndt S, et al. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia. 2020;34:1805–15. https://doi.org/10.1038/s41375-020-0891-0. CAS Article PubMed Google Scholar Download references Division of Hematology, University of Siena, Siena, Italy ...
Alessandro Gozzetti +2 more
openalex +5 more sources
Identification and validation of the association of Janus kinase 2 mutations with the response to immune checkpoint inhibitor therapy. [PDF]
Inflamm ResChen P +7 more
europepmc +3 more sources
The methyl-CpG binding domain 2 regulates peptidylarginine deiminase 4 expression and promotes neutrophil extracellular trap formation via the Janus kinase 2 signaling pathway in experimental severe asthma. [PDF]
Ann MedPeng B +5 more
europepmc +2 more sources
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study [PDF]
The Lancet Haematology, 2017 Claire Harrison +15 more
openalex +2 more sources
Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis.
Cochrane Database of Systematic Reviews, 2015 Myelofibrosis is a bone marrow disorder characterized by excessive production of reticulin and collagen fiber deposition caused by hematological and non-hematological disorders. The prognosis of myelofibrosis is poor and treatment is mainly palliative.
A. Martí-Carvajal +2 more
semanticscholar +5 more sources
Janus kinase inhibitors - their current applications and future prospects [PDF]
Farmacja Polska, 2022 Janus kinase inhibitors are a group of drugs that provide an alternative to conventional therapy for numerous diseases. The most studied drug of this group is tofacitinib.
Natalia Wierzbowska +4 more
doaj +1 more source
Covalent Modification of the JH2 Domain of Janus Kinase 2. [PDF]
ACS Med Chem Lett, 2022 Probe molecules that covalently modify the JAK2 pseudokinase domain (JH2) are reported. Selective targeting of JH2 domains over the kinase (JH1) domains is a necessary feature for ligands intended to evaluate JH2 domains as therapeutic targets. The JH2 domains of three Janus kinases (JAK1, JAK2, and TYK2) possess a cysteine residue in the catalytic ...
Henry SP +6 more
europepmc +3 more sources
Dermatologic Therapy, 2021 Deucravacitinib, a novel, oral, selective inhibitor of tyrosine kinase 2 (TYK2) signaling, acts via an allosteric mechanism by binding to the enzyme’s regulatory domain instead of the catalytic domain.
A. Chimalakonda +10 more
semanticscholar +1 more source
Itch and Janus Kinase Inhibitors
Acta Dermato-Venereologica, 2023 Itch is a common skin symptom, with complex aetiology and pathogenesis. It is mediated by 2 pathways, the histaminergic and non-histaminergic pathways.
Yujin Han +4 more
doaj +1 more source